Novel Regulators of Pancreatic Cancer Cell Growth and Moility (Pehmeäkantinen kirja)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 135ms
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
+ / - Hover over image to Zoom

Maksa erissä alk. 5,00 € / kk


Toimitusaika 3 - 14 arkipäivää

Nouto myymälästä tai pakettiautomaatista alk. 0 €
Toimitus kotiin alk. 2,95 €
Pancreatic cancer is a rare but very aggressive malignancy affecting yearly approximately 1,000 individuals in Finland. Although it accounts only for a little over 3% of all new cancer cases, it is the third leading cause of cancer deaths for both genders. The main cause for the poor prognosis is the fact that the diagnostic and therapeutic tools for pancreatic cancer are truly limited and inefficient. This study aimed to characterize both recurrently amplified chromosomal regions as well as microRNA expression patterns in pancreatic cancer and thus to identify novel putative targets for diagnostic and therapeutic purposes.

Large chromosomal aberrations are typical for most solid tumors, including pancreatic cancer. Recurrently amplified regions are likely to contain genes which contribute to the development of the disease and might thus serve as targets for early detection or treatment of the disease. Here, a detailed characterization of the 7q21 q22 amplicon in pancreatic cancer was performed in order to identify novel target genes. The amplification was found to exist in 25% of both pancreatic cancer cell lines and primary tumors and to result in overexpression of several genes within the amplicon core. Further functional studies on three of the amplified genes, ARPC1A, ARPC1B, and KPNA7 confirmed that these genes do contribute to the pathogenesis of pancreatic cancer.
Kun ostat verkkokaupasta:
  1. 1 Laskulla jopa 60 päivää korotonta maksuaikaa.
  2. 2 Yli 65€ ostoista toimitus veloituksetta myymälään tai pakettiautomaattiin.
  3. 3 Bonus ostoista jopa 5 %
  4. 4 Tuotteilla ilmainen palautusoikeus 14 päivän ajan.